Correction to: Leukemia (2006) 20, 1467–1473. doi:10.1038/sj.leu.2404284
It has been identified by the authors that there are three errors in this paper.
Table 4: Criteria listed under subheading ‘Definitions for measurable disease’ should also include:
‘Bone marrow plasma cells ⩾30%.
Table 5: Bone marrow criteria for CR should be ‘<5% plasma cells’ and not ‘⩽5% plasma cells’.
Table 6: Relapse criteria for progressive disease should state ‘Increase of ⩾25% from lowest response level’ and not ‘Increase of ⩾25% from baseline’.
The authors apologize for these errors.
The online version of the original article can be found at 10.1038/sj.leu.2404284
About this article
JCO Precision Oncology (2018)
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1